Ml. Sassi et al., Immunochemical characterization of assay for carboxyterminal telopeptide of human type I collagen: Loss of antigenicity by treatment with cathepsin K, BONE, 26(4), 2000, pp. 367-373
The assay for the cross-linked carboxyterminal telopeptide of type I collag
en (ICTP) has been shown to reflect increased type I collagen degradation i
n such pathological conditions as bone metastases and rheumatoid arthritis,
but to be rather insensitive to the changes in physiological bone collagen
turnover (e.g., induced by estrogen or bisphosphonate treatment). To deter
mine the reasons for this discrepancy we localized the antigenic determinan
t recognized by the ICTP assay and studied the effects of two major osteocl
astic proteinases, cathepsin K (EC 3.4.22.38) and matrix metalloproteinase-
9 (MMP-9; gelatinase B; EC 3.4.24.35), on immunoreactivity. The antigenic d
eterminant was shown to reside within the hydrophobic phenylalanine-rich re
gions of the carboxyterminal telopeptides of the two alpha 1 chains of huma
n type I collagen, situated between the triple helical domain and the lysin
e-derived trivalent cross-link. This conclusion was based on differences be
tween the amino acid sequences and cross reactivities of the corresponding
human and bovine antigens before and after proteolytic treatments with chym
otrypsin, A trivalent cross-link is necessary for providing such a structur
e, because the divalently cross-linked and monomeric natural and synthetic
peptides from the same region, but containing only one phenylalanine-rich s
equence, showed poor immunoreaction. Recombinant human cathepsin K cleaved
the trivalently cross-linked ICTP structure at two sites between the phenyl
alanine-rich region and the crosslink, destroying the reactivity with ICTP
antibodies. On the contrary, the treatment of isolated ICTP by the matrix m
etalloproteinases MMP-9 (gelatinase B), MMP-1 (collagenase 1), or MMP-13 (c
ollagenase 3) had no effect on the immunoreaction. Our results indicate tha
t the increased circulating concentrations of ICTP found in several clinica
l situations are most likely produced by matrix metalloproteinases, whereas
cathepsin K-mediated, osteoclastic bone resorption destroys ICTP antigenic
ity. (Bone 26:367-373; 2000) (C) 2000 by Elsevier Science Inc. All rights r
eserved.